Quality of Life and Health Economic Assessments of Age-Related Macular Degeneration

D Covert, G Berdeaux, J Mitchell, Clare Bradley and R Barnes

(2007)

D Covert, G Berdeaux, J Mitchell, Clare Bradley and R Barnes (2007) Quality of Life and Health Economic Assessments of Age-Related Macular Degeneration. Survey of Ophthalmology, 52 (1, Supplement 1).

Our Full Text Deposits

Full text access: Open

Full Text - 48.57 KB

Links to Copies of this Item Held Elsewhere

Link to Publisher Copy

Abstract

In this article, we review measures of patient-reported outcomes that can show whether a treatment for age-related macular degeneration also provides patient-perceived benefits. In addition, we look at health economic measurements currently being used to develop cost-effectiveness models for age-related macular degeneration.

Information about this Version

This is a Published version
This version's date is: 01/2007
This item is peer reviewed

Link to this Version

https://repository.royalholloway.ac.uk/items/87517f05-473a-1433-30c3-19fe5a10b344/1/

Item TypeJournal Article
TitleQuality of Life and Health Economic Assessments of Age-Related Macular Degeneration
AuthorsCovert, D
Berdeaux, G
Mitchell, J
Bradley, Clare
Barnes, R
Uncontrolled Keywordsage-related macular degeneration, cost of blindness and cost-effectiveness, low vision, quality of life measures, visual function measures, visual impairment
DepartmentsFaculty of Science\Psychology

Identifiers
doidoi:10.1016/j.survophthal.2006.10.014

Deposited by () on 23-Dec-2009 in Royal Holloway Research Online.Last modified on 12-May-2010

Notes

This is the final draft version of the paper that appeared in Survey of Ophthalmology, Volume 52, Issue 1, January 2007.

References

1. Rubin GS, Bandeen-Roche K, Prasada-Rao P, Fried LP. Visual impairment and disability in older adults. Optom Vis Sci 1994;71:750-760.
2. Park W. Vision rehabilitation for age-related macular degeneration. Int Ophthalmol Clin. 1999 Fall; 39(4): 143-62.
3. Taylor HR, McCarty CA, Nanjan MB, Klein BEK, Spaeth GL, Ferris FL, Mills RP, Ing MR. Vision impairment predicts five-year mortality. Trans Am Ophthalmol Soc. 2000;98:91-99.
4. Phillips KA, Cockrum PC, Kennedy RH. Worldwide blindness and prevention guidelines for front-line practitioners. Today’s Therapeutic Trends 2003;21(1):71-83.
5. Williams RA, Brody BL, Kaplan RM, et al. The psychosocial impact of macular degeneration. Arch Ophthalmol. 1998;116:514-520.
6. Klein R, Peto T, Bird A, Vannewkirk MR. Perspective: The epidemiology of age-related macular degeneration. Am J Ophthalmol 2004;137:486-495.
7. Age-Related Eye Disease Study Research Group. Potential public health impact of age-related eye disease study results – AREDS Report No. 11. Arch Ophthalmol 2003;121:1621-1624..
8. The Anecortave Acetate Clinical Study Group. Anecortave Acetate as monotherapy for the treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology 2003;110:2372-2385.
9. Mangione CM, Berry S, Spritzer K, Janz NK, Klein R, Owsley C, Lee PP. Identifying the content area for the 51-item National Eye Institute Visual function Questionnaire. Arch Ophthalmol. 1998;116:227-223.
10. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD et al. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119:1050-1058.
11. Mangione CM, Phillips RS, Seddon JM, Lawrence MG, Cook EF, Dailey R, Goldman L. Development of the “Activities of Daily Vision Scale”: A measure of visual functional status. Med Care 1992;30:1111-1126.
12. Cassard SD, Patrick DL, Damiano AM, Legro MW, Tielsch JM, Diener-West M, Schein OD, Javitt JC, Bass EB, Steinberg EP. Reproducibility and responsiveness of the VF-14; An index of functional impairment in patients with cataracts. Arch Ophthalmol 1995;113:1508-1513.
13. Ware Jr JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. The Health Institute, New England Medical Center, Boston, MA, 1993.
14. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQoL Group. Ann Med. 2001;33(5):337-43.
15. Mangione CM, Lee PP, Pitts J, Gutierrez P, Berry S, Hays RD. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). Arch Ophthalmol. 1998;116:1496-1504.
16. Rubin GS, Bandeen-Roche K, Guan-Hua H, Murioz B, Schein OD, Fried LP, West SK. The association of multiple visual impairments with self-reported visual disability: SEE project. IOVS 2001; 42 (1): 64-72
17. Mitchell J, Bradley C. Design of an individualised measure of the impact of macular disease on quality of life (the MacDQoL). Qual Life Res. 2004;13:1163-1175.
18. Bradley C, Todd c, Gorton T, Symonds L, Martin A, Plowright R. The development of an individualised questionnaire measure of perceived impact of diabetes on quality of life: the ADDQoL. Qual Life Res. 1999;8:79-91.
19. McGee HM, O’Boyle CA, Hicky A, O’Malley K, Joyce CRB. Assessing the quality of life of the individual: the SEIQOL with a healthy and a gastroenterology unit population. Psychol Med. 1991;21:749-759.
20. Mitchell J, Wolffsohn JS, Woodcock A, Anderson SJ, McMillan CV, ffytche T, Rubinstein M, Amoaku W and Bradley C. Psychometric evaluation of the MacDQoL individualised measure of the impact of macular degeneration on quality of life. Health and Quality of Life Outcomes; in press.
21. Bradley C. The Well-being Questionnaire. In: Bradley C (ed), The Handbook of Psychology and Diabetes: A guide to psychological measures in diabetes research and practice, Chur, Switzerland: Harwood Academic Press, 1994;89-109.
22. Witthaus E, Stewart J, Bradley C. Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetes. Diabetic Medicine 2001;18(8):619-625
23. McMillan CV, Bradley C, Gibney J, Russell-Jones DL, Sonksen PH. Measuring psychological well-being in adult growth hormone deficency. Proceedings of the British Psychological Society 2001;9(1):71.
24. Plowright R, Witthaus E, Bradley C. Evaluating the 12-item Well-being Questionnaire for use in multinational trials. Qual Life Res 1999;8(7):650.
25. Pouwer F, Snoek FJ, van der Ploeg HM, Ader HJ, Heine RJ. The Well-being Questionnaire: Evidence for a three-factor structure with 12 items (W-BQ12). Psychol Med. 2000;30:455-462.
26. Pouwer F, van der Ploeg HM, Ader HJ, Heine RJ, Snoek FJ. The 12-Item Well-being Questionnaire: An evaluation of its validity and reliability in Dutch people with diabetes. Diabetes Care 1999;22(12):2004-2010.
27. Bradley C. The 12-item Well-being Questionnaire. Diabetes Care 2000;23(6):875.
28. Speight J, Barendse S, Bradley C. Impact of positively and negatively worded items on the factor structure of three psychological measures: W-BQ22, W-BQ12 & SF-36. Qual Life Res. 1999;8:576.
29. Mitchell J, Bradley P, Anderson SJ, Ffytche T, Bradley C. Perceived quality of health care in macular disease: A survey of members of the Macular Disease Society. Br J Ophthalmol. 2002;86(7):777-781.
30. Mitchell J, Bradley C. Psychometric evaluation of the 12-item Well-being Questionnaire for use with people with macular disease. Qual Life Res. 2001;10:465-473.
31. Smith AF, Smith JG. The economic burden of global blindness: a price too high! Br J Ophthalmol. 1996;80:276-277.
32. Meads C, Hyde C. What is the cost of blindness? Br J Ophthalmol. 2003;87:1201-1204.
33. Frick KD, Foster A. The magnitude and cost of global blindness: An increasing problem that can be alleviated. Am J Ophthalmol. 2003;135:471-476.
34. Bonastre J, Le Pen C, Anderson P, Ganz A, Berto P, Berdeaux G. Epidemiology, economics, and the quality of life burden of age-related macular degeneration in four European countries: France, Italy, Germany and the United Kingdom. The European Journal of Health Economics 2002;3(2):94-102.
35. Brezin A, Lafuma A, Fagnani F, Mesbah M, Berdeaux G. Prevalence and burden of blindness, low vision and visual impairment in the community: a nation-wide survey. (Archives of Ophthalmology, in press).
36. Brezin A, Lafuma A, Fagnani F, Mesbah M, Berdeaux G. Blindness, low vision and other handicaps as risk factors of institution. Br J Ophthalmol 2004;88(10):1330-1337.
37. Brown GC, Brown MM, Sharma S, Brown H, Tasman W. Incremental cost effectiveness of laser photocoagulation for subfoveal choroidal neovascularization. Ophthalmology 2000;107:1374-1380.
38. Sharma S, Brown GC, Brown MM, Hollands H, Shah G. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2001;108:2051-2059.
39. National Institute for Clinical Excellence. Guidance on the use of photodynamic therapy for age-related macular degeneration. Technology Appraisal Guidance 68. September 2003. Reference N0305.

Details